Antibacterials and acute exacerbation of chronic bronchitis

Issues for formulary decision makers

Alan Chock, Vera Gong, Christopher J. Destache

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The utility of antibacterials in the management of acute exacerbations of chronic bronchitis (AECB) and the related lung pathology, chronic obstructive pulmonary disease (COPD), has been debated for decades. Data presented in this article document that more expensive antimicrobials may be favored in AECB treatment to prevent adverse outcomes to patients, namely antimicrobial failure and hospitalization. Identified patient-specific variables that may lead to treatment failure include right- or left-sided heart failure and ≥4 exacerbations/year. Risk factors for hospitalization include age ≥65 years and severe pulmonary and nonpulmonary dysfunction. However, these risk factors have never been formally validated in a prospective, randomized trial. Drug-resistant organisms have not been documented to cause antimicrobial failure or hospitalization, however, more data are needed in this growing area.

Original languageEnglish
Pages (from-to)333-336
Number of pages4
JournalDisease Management and Health Outcomes
Volume10
Issue number6
StatePublished - 2002

Fingerprint

Formularies
Chronic Bronchitis
Hospitalization
Lung
Treatment Failure
Chronic Obstructive Pulmonary Disease
Heart Failure
Pathology
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Nursing(all)

Cite this

Antibacterials and acute exacerbation of chronic bronchitis : Issues for formulary decision makers. / Chock, Alan; Gong, Vera; Destache, Christopher J.

In: Disease Management and Health Outcomes, Vol. 10, No. 6, 2002, p. 333-336.

Research output: Contribution to journalReview article

@article{3fdbb45ab1c943b0861f8a70b31bd710,
title = "Antibacterials and acute exacerbation of chronic bronchitis: Issues for formulary decision makers",
abstract = "The utility of antibacterials in the management of acute exacerbations of chronic bronchitis (AECB) and the related lung pathology, chronic obstructive pulmonary disease (COPD), has been debated for decades. Data presented in this article document that more expensive antimicrobials may be favored in AECB treatment to prevent adverse outcomes to patients, namely antimicrobial failure and hospitalization. Identified patient-specific variables that may lead to treatment failure include right- or left-sided heart failure and ≥4 exacerbations/year. Risk factors for hospitalization include age ≥65 years and severe pulmonary and nonpulmonary dysfunction. However, these risk factors have never been formally validated in a prospective, randomized trial. Drug-resistant organisms have not been documented to cause antimicrobial failure or hospitalization, however, more data are needed in this growing area.",
author = "Alan Chock and Vera Gong and Destache, {Christopher J.}",
year = "2002",
language = "English",
volume = "10",
pages = "333--336",
journal = "Disease Management and Health Outcomes",
issn = "1173-8790",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Antibacterials and acute exacerbation of chronic bronchitis

T2 - Issues for formulary decision makers

AU - Chock, Alan

AU - Gong, Vera

AU - Destache, Christopher J.

PY - 2002

Y1 - 2002

N2 - The utility of antibacterials in the management of acute exacerbations of chronic bronchitis (AECB) and the related lung pathology, chronic obstructive pulmonary disease (COPD), has been debated for decades. Data presented in this article document that more expensive antimicrobials may be favored in AECB treatment to prevent adverse outcomes to patients, namely antimicrobial failure and hospitalization. Identified patient-specific variables that may lead to treatment failure include right- or left-sided heart failure and ≥4 exacerbations/year. Risk factors for hospitalization include age ≥65 years and severe pulmonary and nonpulmonary dysfunction. However, these risk factors have never been formally validated in a prospective, randomized trial. Drug-resistant organisms have not been documented to cause antimicrobial failure or hospitalization, however, more data are needed in this growing area.

AB - The utility of antibacterials in the management of acute exacerbations of chronic bronchitis (AECB) and the related lung pathology, chronic obstructive pulmonary disease (COPD), has been debated for decades. Data presented in this article document that more expensive antimicrobials may be favored in AECB treatment to prevent adverse outcomes to patients, namely antimicrobial failure and hospitalization. Identified patient-specific variables that may lead to treatment failure include right- or left-sided heart failure and ≥4 exacerbations/year. Risk factors for hospitalization include age ≥65 years and severe pulmonary and nonpulmonary dysfunction. However, these risk factors have never been formally validated in a prospective, randomized trial. Drug-resistant organisms have not been documented to cause antimicrobial failure or hospitalization, however, more data are needed in this growing area.

UR - http://www.scopus.com/inward/record.url?scp=0036288560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036288560&partnerID=8YFLogxK

M3 - Review article

VL - 10

SP - 333

EP - 336

JO - Disease Management and Health Outcomes

JF - Disease Management and Health Outcomes

SN - 1173-8790

IS - 6

ER -